- Pre-clinical phase
- Phase-I
- Phase II
- Phase-III
RNA Vaccines Pipeline Analysis Market size was valued at USD x million in 2021 and is expected to reach USD x million by 2028, at a CAGR of x% during the forecast period 2022 to 2028. Due to increase in prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries, Â rise in funding for the development of RNA vaccines from public and private sectors, promising pipeline drugs, and wide range of applications with RNA vaccines are the major factors that are driving the growth of the global RNA vaccines market over the forecast timeframe. The report studies global RNA vaccines dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global RNA vaccines market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global RNA vaccines market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global RNA vaccines market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA vaccines products.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA vaccines market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi vaccines, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA vaccines market over the forecast years.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.